Katherine Talcott, MD; Akshay Thomas, MD; and Nita Valikodath, MD, MS
Show Description +
What can pharmacovigilance data tell us about the post-marketing safety profiles of anti-VEGF agents, and where do those signals fall short? In this episode of New Retina Radio Journal Club with VBS, Katherine Talcott, MD, moderates a discussion with Akshay Thomas, MD, and Nita Valikodath, MD, MS, on a 2026 study comparing ocular adverse event reporting for aflibercept 2 mg (Eylea, Regeneron), aflibercept 8 mg (Eylea HD, Regeneron), and faricimab (Vabysmo, Genentech/Roche) using the FDA Adverse Event Reporting System. The group examines distinct signal profiles for each agent and makes the case for why these findings should be viewed as hypothesis-generating rather than evidence of causality.
Posted: 8/20/2026
Katherine Talcott, MD; Akshay Thomas, MD; and Nita Valikodath, MD, MS
What can pharmacovigilance data tell us about the post-marketing safety profiles of anti-VEGF agents, and where do those signals fall short? In this episode of New Retina Radio Journal Club with VBS, Katherine Talcott, MD, moderates a discussion with Akshay Thomas, MD, and Nita Valikodath, MD, MS, on a 2026 study comparing ocular adverse event reporting for aflibercept 2 mg (Eylea, Regeneron), aflibercept 8 mg (Eylea HD, Regeneron), and faricimab (Vabysmo, Genentech/Roche) using the FDA Adverse Event Reporting System. The group examines distinct signal profiles for each agent and makes the case for why these findings should be viewed as hypothesis-generating rather than evidence of causality.
Posted: 8/20/2026
New Retina Radio is forging forward with education, and they’re partnering with Vit Buckle Society to make it happen. Check out these quick-hit reviews of journal articles delivered by VBS members.
Comparing Ocular AEs in Next-Gen Treatments
Katherine Talcott, MD; Akshay Thomas, MD; and Nita Valikodath, MD, MS
Please log in to leave a comment.